Kimberly-Clark Kenvue Deal After EU Approval: Why a 14x Forward P/E and a 4.8% Yield Point to a $114 Target

Table of Contents

The Kimberly-Clark Kenvue deal just cleared one of its last big hurdles, and the stock finally noticed. On October 14, 2026, the European Commission approved Kimberly-Clark Corporation’s (NASDAQ: KMB) planned acquisition of Kenvue Inc. (NYSE: KVUE), the maker of Tylenol, Listerine, Neutrogena and Band-Aid. The one condition is that Kimberly-Clark sell its tampon and other feminine hygiene brands in the European market. The next morning, October 15, Kimberly-Clark filed preliminary third-quarter 2026 results with the SEC. They showed adjusted EPS of $1.70 against a consensus of roughly $1.59–$1.60, and net sales of about $4.13 billion, ahead of the ~$4.1 billion analysts expected. The company also kept its full-year 2026 outlook unchanged. The shares rose about 3.7% in pre-market trading that day, and CNBC described it as Kimberly-Clark’s best week in four years. Money was rotating out of AI-linked technology names and into defensive sectors.

Even after that move, KMB closes the week at $105.57. That is about 14% below its 52-week high of $123.09, and it values the company at only 14.35 times consensus forward earnings. Procter & Gamble, Colgate-Palmolive and Church & Dwight all trade between 21.6x and 25.9x forward earnings. Kimberly-Clark also pays a $1.28 quarterly dividend ($5.12 annualized), a 4.85% yield, and it has raised that dividend for 54 consecutive years.

We think three investment points matter most.

1. The Kimberly-Clark Kenvue deal is moving from “if” to “when.” Shareholders of both companies approved it on January 29, 2026. The U.S. HSR waiting period expired on February 4, and the EU has now signed off. At Friday’s close, the deal consideration of 0.14625 KMB shares plus $3.50 in cash is worth about $18.94 per Kenvue share. Kenvue trades at $18.91. A spread of about three cents means the market now treats completion as close to certain.

2. The synergy math is large relative to today’s market value. Management has identified about $1.9 billion of cost synergies and about $500 million of revenue-synergy profit, less roughly $300 million of reinvestment. That is about $2.1 billion of net run-rate benefit, set against a combined company that would have a market value of only about $65 billion at today’s price.

3. The China problem may prove temporary, and the Q3 beat supports that view. Social-media claims that Huggies diapers contained formamide forced a guidance cut in August. In August the company said independent testing by a government-certified third party found no formamide; China’s market regulator opened an investigation in June and has not published a finding. Any recovery in China comes on top of a valuation that already assumes the problem lasts.

This article covers Kimberly-Clark’s business model and segment mix, the household and personal-care industry in depth (market size, growth drivers and competitors), the durability of its brand and scale moat, three years of restated financial trends plus the trailing twelve months, a step-by-step valuation with bull, base and bear cases, the three risks that could break the thesis, and a concrete entry and exit plan.

1. Company Overview: How Kimberly-Clark Makes Money

Kimberly-Clark is a 150-year-old consumer-products company that sells everyday essentials in more than 175 countries and territories. Its brands include Huggies diapers and Pull-Ups training pants, Kleenex tissues, Scott and Cottonelle bath tissue, Kotex feminine care, and Depend and Poise adult incontinence products. According to the company, its brands hold the No. 1 or No. 2 share position in about 70 countries.

The business model is simple to describe and hard to copy. Kimberly-Clark converts pulp, superabsorbent polymers and nonwoven fabrics into high-volume, low-ticket products that households replace every few days or weeks. Its profit comes from three sources:

– Brand premium. Consumers pay more for a trusted diaper or tissue brand than for private label, especially when the product touches a baby’s skin.
– Manufacturing scale. Huge, continuously running converting lines spread fixed costs over billions of units.
– Retail distribution. It holds shelf space with Walmart, Costco, Target, Amazon and grocery chains, which is very hard for a new entrant to win.

The 2026 portfolio is different from the one most investors remember. On July 1, 2026, Kimberly-Clark completed the transfer of its International Family Care and Professional business (IFP) into a joint venture with Suzano S.A. Suzano bought 51%, and Kimberly-Clark kept a 49% stake that its Q2 10-Q valued at about $1.2 billion. The company expects to book a pre-tax gain of more than $1.0 billion on the transaction in the third quarter. IFP is now reported as a discontinued operation. The remaining business has two reporting segments:

Segment (6M 2026, continuing operations)	Net Sales	Share of Sales	Segment Operating Profit	Segment Margin
North America	$5,349M	64%	$1,348M	25.2%
International Personal Care (IPC)	$3,003M	36%	$431M	14.4%
Total	$8,352M	100%	$1,779M (before $393M corporate & other)	—

Source: Kimberly-Clark Q2 2026 Form 10-Q. Segment margin = segment operating profit ÷ segment net sales.

North America is the profit engine. Its margins are roughly 25%, because Huggies, Cottonelle, Kleenex and Depend all hold leading positions in a mature, rational retail market. International Personal Care, which covers diapers, feminine care and adult care in Latin America, Asia and other regions, grows faster in good years but is more volatile. This year’s China disruption is a clear example. In Q2 2026, North America sales slipped to $2,698 million from $2,730 million, while IPC sales rose to $1,491 million from $1,433 million.

Customers are mostly large retailers and e-commerce platforms. That concentrates bargaining power on the buying side, which is one reason brand strength matters so much. On governance and ownership, Kimberly-Clark is a widely held large-cap stock. The company says it is held by more than 400 ETFs, and index funds and large institutions own most of the float. The diluted share count has been essentially flat at about 333 million in 2025–2026, because buybacks paused in 2026 ahead of the Kenvue deal. They fell to $141 million in 2025 from $1.0 billion in 2024.

2. Industry Analysis: Household and Personal Care in a Low-Growth, High-Moat World

2-1. Market Size and Growth Trajectory

Kimberly-Clark’s core categories are absorbent hygiene and tissue. These are large, global and growing slowly, which is typical of a mature consumer staple. Fortune Business Insights estimates the global diaper market, covering both baby and adult products, at about $80.9 billion in 2025 and expects it to grow at about 3.2% a year through 2034. Other research houses use different definitions and produce higher numbers. ResearchAndMarkets puts the 2024 figure near $99 billion with roughly 6% annual growth. The useful point is not the exact number but its shape: a market of $80–100 billion growing in the low-to-mid single digits.

The adult incontinence sub-category is growing faster. Coherent Market Insights estimates the adult diaper market at about $18.7 billion in 2025 and projects a 7.3% compound annual growth rate through 2032. Other vendors estimate between roughly $15.6 billion and $20.9 billion for 2025, with growth rates between about 6.5% and 9.5%. Kimberly-Clark’s Depend and Poise brands sit squarely in this faster-growing segment.

Kimberly-Clark’s own measure is more conservative and more useful. It tracks the “weighted average category growth” across the specific categories and countries where it competes. That figure is currently about 1.7% on a trailing 12-month basis, according to the October 15 release. Management now expects 2026 organic sales growth about 100 basis points below that, a gap it attributes almost entirely to China.

Where are these categories in their cycle? Baby diapers in North America, Western Europe and China are in late maturity, because birth rates in all three regions are flat to declining. Adult incontinence is still accelerating as populations age. Over-the-counter health and skin care, the categories Kenvue adds, sit in between: they are mature in developed markets but have a richer price and mix profile and higher gross margins. Kenvue’s adjusted gross margin was 60.2% in 2025, against about 36% for Kimberly-Clark. This combination is the strategic logic of the Kimberly-Clark Kenvue deal: a low-growth, low-gross-margin tissue and diaper business acquires a higher-margin health-and-wellness portfolio and spreads its distribution and supply-chain scale across both.

2-2. Structural Growth Drivers

Driver 1: Aging populations and the adult-care opportunity. Demographics are the most predictable force in consumer staples. The number of people over 65 is rising in nearly every developed market and in China, and incontinence affects a meaningful share of older adults. Adult care also has better economics than baby care. Usage lasts years rather than the two to three years of a diaper cycle. Social stigma means consumers pay for discretion, comfort and brand trust rather than shopping on price. Growing e-commerce penetration also reduces the embarrassment of buying these products in a store. This is why third-party estimates for adult care cluster in the 6–9% annual growth range, two to three times the rate for baby diapers. Kimberly-Clark’s Depend and Poise franchises put it in a strong position to benefit. The driver is long-term (5–10 years) and steady, and it does not depend on the economic cycle.

Driver 2: Premiumization and innovation in a slow-volume market. When unit volumes grow only 0–2%, revenue growth comes mainly from price and mix. Premium tiers, such as thinner and more absorbent diapers, sensitive-skin wipes, softer bath tissue and discreet adult underwear, carry higher prices and higher margins. The company’s 2024 Transformation Initiative, which it has extended through 2028 at a total estimated pre-tax cost of about $1.5 billion, aims to free up savings that can be reinvested in this kind of innovation and marketing. The evidence so far is encouraging: gross margin expanded to 37.6% in the first half of 2026 from 36.1% a year earlier. In the short term this driver is challenged, because North American consumers under inflation pressure trade down, and Q2 North American volumes fell 0.3% according to Reuters. Over the long term, premiumization is the main way mature staples companies have grown earnings faster than sales.

Driver 3: Portfolio reshaping toward health and wellness through the Kimberly-Clark Kenvue deal. The acquisition, at an enterprise value of $48.7 billion, would roughly double the company’s revenue to about $32 billion. According to the November 2025 announcement, the combined company would have about $32 billion of 2025 net revenue, about $7 billion of adjusted EBITDA and 10 brands with more than $1 billion in sales each. Kenvue’s trailing revenue is $15.41 billion according to Finviz, almost as large as Kimberly-Clark’s $16.58 billion. Its operating margin is also higher: 19.24% TTM versus 14.24%. Over the medium term (2027–2029), the combined company should be able to:

1. Remove overlapping corporate, procurement and logistics costs. This accounts for most of the $1.9 billion cost-synergy target, which is due within three years of closing.
2. Sell Kenvue’s brands through Kimberly-Clark’s distribution in emerging markets, and the reverse.
3. Use joint scale in advertising and retail negotiations.

The cost of reaching these synergies is about $2.5 billion of one-time cash.

Driver 4: Emerging-market household formation. In parts of Latin America, Southeast Asia, Africa and the Middle East, disposable-diaper and feminine-care penetration is still well below developed-market levels. Rising incomes push more households from cloth and unbranded products to branded ones. Kimberly-Clark’s IPC segment, with 36% of continuing sales, is built to capture this. It is volatile because of currency swings and episodes like the 2026 China disruption, but over a decade it is the main source of volume growth.

Short-term versus long-term dynamics. In the next 12 months, the category picture is unexciting: about 1.7% category growth, a squeezed North American consumer and a China recovery that has not yet been proven. The stock’s next move will come mostly from the deal closing, early synergy delivery and the first combined guidance. Over a five-year horizon, demographics, premiumization and the health-and-wellness mix shift support mid-single-digit earnings growth, before adding synergies.

2-3. Competitive Landscape

The household and personal-care industry is an oligopoly in most categories. A few global players hold the largest brands, regional specialists compete in certain markets, and retailers’ private labels attack the value tier. Here is how Kimberly-Clark compares with its U.S.-listed peers on trailing data from Finviz:

Company	Market Cap	TTM Sales	TTM Operating Margin	Forward P/E	Key Moat
Kimberly-Clark (KMB)	$35.11B	$16.58B	14.24%	14.35x	Brands (Huggies, Kleenex, Depend) + converting scale
Procter & Gamble (PG)	$370.12B	$87.03B	23.86%	21.58x	Brand portfolio breadth + R&D + scale
Colgate-Palmolive (CL)	$75.02B	$21.05B	21.84%	23.05x	Oral-care brand + emerging-market distribution
Kenvue (KVUE)	$36.32B	$15.41B	19.24%	15.18x	OTC health brands (Tylenol, Listerine, Neutrogena)
Church & Dwight (CHD)	$24.79B	$6.23B	17.47%	25.87x	Niche category brands (Arm & Hammer)
Clorox (CLX)	$10.53B	$6.72B	13.21%	14.18x	Brands (Clorox, Glad, Kingsford)

Source: Finviz, data as of October 16, 2026 close.

Three things stand out.

First, Kimberly-Clark trades at a deep discount to the higher-quality peers. The average forward P/E for P&G, Colgate and Church & Dwight is about 23.5x. KMB’s 14.35x is roughly 39% below that. Part of this discount is justified. Kimberly-Clark’s operating margin of about 14% is well below P&G’s ~24% and Colgate’s ~22%, because tissue and diapers are more commodity-like than detergents or toothpaste, and pulp costs flow straight through to margins. Part of it, in our view, is overdone. It reflects merger uncertainty, the China scare and fear of Tylenol litigation inherited from Kenvue, and the first two are now fading.

Second, the acquirer is smaller than its target. Kenvue’s $36.32 billion market cap is slightly larger than Kimberly-Clark’s $35.11 billion. After closing, former Kenvue shareholders will own roughly 46% of the combined company, based on about 280 million new shares against 332.6 million existing ones. This is effectively a merger of equals in scale.

Third, P&G remains the benchmark. P&G competes directly with Huggies through Pampers, with Kleenex through Puffs, with Cottonelle through Charmin, and in adult care through Always Discreet. Even after the Kenvue deal, the combined Kimberly-Clark’s roughly $32 billion of revenue will be well under half of P&G’s $87 billion. Outside the U.S., Kimberly-Clark also faces strong regional competitors, such as Essity in Europe and Unicharm in Asia, as well as fast-growing Chinese local brands in diapers.

Why Kimberly-Clark is reasonably positioned. In North America, diapers and tissue are concentrated among a small number of branded players plus retailer private label, a structure that has historically discouraged destructive price wars. Kimberly-Clark’s segment margin of more than 25% there shows how healthy that structure is. The Kenvue deal adds categories (OTC pain relief, oral care, skin health) where Kimberly-Clark does not compete with P&G as directly and where gross margins are around 60%. The combined portfolio is therefore less exposed to pulp costs and private-label pressure than Kimberly-Clark on its own.

3. Economic Moat Analysis

Moat Type 1: Intangible Assets — Trusted Brands in Products That Touch the Body

The most important source of Kimberly-Clark’s advantage is brand trust in categories where failure is personal. A parent choosing a diaper is not optimizing price per unit. They are buying confidence that the product will not leak, irritate the skin or contain anything harmful. The same applies to adult incontinence and feminine care. This is why branded products hold their position against cheaper private labels despite years of retailer pressure.

The evidence is in the numbers. Kimberly-Clark says it holds No. 1 or No. 2 share positions in about 70 countries. Its North America segment earned a 25.2% operating margin in the first half of 2026, a level that would be impossible if consumers saw these products as commodities. The company has also passed through cost inflation over the past several years while keeping gross margin around 36–37%: 36.6% in 2023, 37.4% in 2024 and 36.0% in 2025, rising to 37.6% in the first half of 2026.

The 2026 China episode actually shows how valuable that trust is, and how fragile. When unverified social-media claims linked Huggies to formamide in June, demand fell sharply. COO Russ Torres said the disruption would cut International Personal Care organic growth by three to four points this year. A brand built over decades took a measurable hit from a few weeks of rumor. The company has said independent third-party retesting found no formamide; China’s regulator has not published a finding. The recovery in China over the next several quarters will be a direct test of brand resilience.

Kenvue strengthens this moat. Tylenol, Listerine, Band-Aid, Neutrogena, Aveeno and Johnson’s are widely known consumer-health brands. Several, such as Tylenol and Listerine, are frequently recommended by healthcare professionals, which adds a layer of professional endorsement that a diaper or tissue brand does not have.

Moat Type 2: Cost Advantage and Efficient Scale in Manufacturing and Distribution

The second advantage is scale. Diaper and tissue manufacturing requires expensive, high-speed lines that need to run continuously to be profitable. A new entrant would have to fund that capacity, then fill it with enough volume to match incumbent unit costs, while also paying for shelf space and advertising. In North America, a small number of established branded players and private-label converters already serve most of the demand. That makes it close to an “efficient scale” market: a new large branded entrant would struggle to earn an adequate return.

Distribution scale matters just as much. Kimberly-Clark ships enormous volumes of bulky, low-value-per-cubic-foot products. Its logistics network, retailer relationships and data on shelf performance are built over decades. The Transformation Initiative, which it expects to involve a 4–5% workforce reduction, is designed to push these costs down further. The Kenvue acquisition would add about $15 billion of higher-value products to the same network. That is a big part of how management plans to reach the $1.9 billion cost-synergy target within three years.

Moat Durability Assessment

Will this moat hold for 5–10 years? We think it will narrow somewhat but not break. There are three threats.

1. Private label and retailer power. Costco’s Kirkland Signature, Amazon’s private brands and Walmart’s store brands keep improving. If quality gaps disappear, the price premium could shrink. Counterargument: private label has existed in diapers and tissue for decades, and branded share in sensitive categories has stayed stable. North American margins above 25% do not suggest a brand losing pricing power.
2. Digital-native and local challengers. In China especially, local diaper brands sold through social commerce have grown quickly, and the 2026 formamide episode showed how fast online sentiment can turn. Counterargument: the same scrutiny also hit Chinese brands such as Babycare and Bibabebe, and Kimberly-Clark’s own third-party retesting found no formamide, although China’s regulator has not yet published a finding. Over time, multinational quality standards can be an advantage in a market where consumers worry about safety.
3. Litigation risk attached to Kenvue’s brands. Tylenol is a powerful brand, but the autism litigation and political attention around acetaminophen show that consumer-health brands carry their own risks. A long legal fight could weaken one of the deal’s most important assets.

Overall, we see a narrow but durable moat. It rests on brand trust and scale, and the Kenvue deal should broaden it. It is clearly narrower than P&G’s, which is why we do not argue that Kimberly-Clark deserves a P&G multiple. What we argue is that a 39% discount is too wide.

투자 분석 이미지 — Photo by Šárka Hyková on Unsplash

4. Financial Analysis

The table below uses Kimberly-Clark’s restated continuing-operations figures from its FY2025 10-K. These exclude the IFP business that moved into the Suzano joint venture. Older years (2021–2022) were reported on the previous basis, which included IFP, so they are not comparable. We therefore show three restated years plus the trailing twelve months.

Fiscal Year	Net Sales	YoY	Gross Profit	Gross Margin	Operating Profit	Operating Margin	Net Income (attrib.)	Diluted EPS (cont. ops)
2023	$17,146M	—	$6,269M	36.6%	$1,928M	11.2%	$1,764M	$4.31
2024	$16,805M	-2.0%	$6,289M	37.4%	$2,700M	16.1%	$2,545M	$6.41
2025	$16,447M	-2.1%	$5,923M	36.0%	$2,351M	14.3%	$2,021M	$4.86
TTM (to Q2 2026)	$16.58B	—	—	36.76%	—	14.24%	$1.96B	EPS (ttm) $5.87

Sources: Kimberly-Clark FY2025 Form 10-K and 2026 10-Qs (SEC XBRL); TTM from Finviz. Net income attributable to Kimberly-Clark includes discontinued operations; EPS shown for 2023–2025 is from continuing operations.

The story behind each year.
– 2023: a depressed base. Operating profit was $1.93 billion, an 11.2% margin and the weakest of the three restated years, but that margin was depressed by a $658 million intangible-asset impairment.
– 2024: a one-time boost. Reported operating profit rose about 40% to $2.70 billion while sales slipped 2.0%, but mostly because of one-time items: 2023 included a $658 million intangible impairment and 2024 included a $448 million gain on asset sales. Gross profit was almost flat ($6.27B → $6.29B), so the underlying improvement was modest.
– 2025: a transition year. According to the company, organic sales grew 1.7%, driven by volume, but reported sales fell 2.1% because of the divestitures. Operating profit fell to $2.35 billion as transformation and deal-related costs rose. Fourth-quarter adjusted EPS of $1.86 was up 24% year over year, which suggests the underlying earnings power improved late in the year.
– 2026 so far: first-half sales rose 1.6% to $8,352 million, and operating profit rose 13.3% to $1,386 million. Q2 adjusted EPS of $1.80 missed the $2.01 consensus because of the China disruption. Preliminary Q3 adjusted EPS of $1.70 then beat the ~$1.59 consensus, on net sales of $4.134 billion, down 0.4%, with organic sales down 1.3%. Final Q3 results come on November 5. GAAP Q3 EPS will be inflated by the pre-tax gain of more than $1.0 billion on the IFP transaction, so investors should focus on adjusted figures.

Key operating metrics. For Kimberly-Clark, the metrics that matter are organic sales growth (volume plus price and mix), gross margin and segment operating margin. Currently:
– Category growth is about 1.7%. The company expects to grow about 100 basis points below that in 2026 because of China.
– Gross margin was 37.6% in the first half of 2026.
– North America segment margin was 25.2% and IPC segment margin was 14.4% (6M 2026).
– 2026 guidance is mid-single-digit growth in adjusted operating profit and high-single-digit growth in adjusted EPS from continuing operations, both in constant currency. Adjusted EPS attributable to Kimberly-Clark is guided to a low-single-digit decline, because the IFP earnings no longer count.

Balance sheet and cash flow. As of June 30, 2026:
– Long-term debt was $6,474 million, and debt due within one year was only $43 million.
– Cash from continuing operations was $956 million ($1,363 million including discontinued operations).
– Net debt was about $5.6 billion.
– Shareholders’ equity was only $1,750 million, a result of decades of buybacks. That is why Debt/Equity reads 3.72 and ROE reads 111.55% on Finviz. These ratios say more about accounting equity than about financial risk.

Cash flow is the more relevant measure:

Year	Operating Cash Flow	Capital Spending	Free Cash Flow	Dividends Paid	Dividends ÷ FCF
2024	$3,234M	$721M	$2,513M	$1,628M	65%
2025	$2,777M	$1,138M	$1,639M	$1,660M	101%
6M 2026	$1,653M	$776M	$877M	$843M	96%

Source: Kimberly-Clark FY2025 10-K and Q2 2026 10-Q (SEC XBRL), consolidated basis.

The 2025–2026 dividend coverage is tight. Capital spending has been elevated by supply-chain investments and transformation projects, and transformation and deal costs have weighed on operating cash flow. A 54-year dividend-growth record means management will defend the dividend. But the company needs free cash flow to recover toward 2024 levels, and needs Kenvue’s cash flow plus synergies, to restore a comfortable cushion. This is one of the most important things to watch after the deal closes.

Margin-expansion path. Kimberly-Clark is already profitable, so the question is margin expansion. Three things support it:
1. Gross margin recovery as transformation savings continue. The first half of 2026 was already 150 basis points higher than a year earlier.
2. The mix shift toward Kenvue’s 58%+ gross margin and 19%+ operating margin categories.
3. Cost synergies of $1.9 billion, which alone would equal more than 5% of combined revenue at full run-rate.

5. Valuation: Step by Step

Step 1: Starting point (Finviz data as of October 16, 2026).
– Price: $105.57
– Market cap: $35.11 billion
– Shares outstanding: 332.56 million
– EPS (ttm): $5.87, giving a P/E of 17.99x ($105.57 ÷ $5.87)
– Consensus EPS next year: $7.36, giving a forward P/E of 14.35x ($105.57 ÷ $7.36)
– Consensus price target: $113.64

Self-check: 332.56 million shares × $105.57 ≈ $35.11 billion, which matches the reported market cap. TTM net income of $1.96 billion ÷ 332.56 million shares ≈ $5.89, close to the reported $5.87.

TTM EPS is distorted by transformation, separation and deal costs, so forward consensus EPS ($7.36) is the right basis for valuation. Trailing GAAP earnings understate the business’s run-rate.

Step 2: Choose the right multiple. Kimberly-Clark trades at 14.35x forward earnings. The relevant comparisons are:
– Clorox at 14.18x and Kenvue at 15.18x: the “challenged staples” group.
– P&G at 21.58x, Colgate at 23.05x and Church & Dwight at 25.87x: the “quality compounders.”

We do not think KMB deserves a quality-compounder multiple while its organic growth trails its categories and its dividend uses almost all of its free cash flow. But once the Kenvue deal closes and the first synergies show up, a modest re-rating toward 15–16x is reasonable. That would still be well below the quality peers.

Step 3: Base case — 15.5x × $7.36 = $114. Applying 15.5x to consensus forward EPS of $7.36 gives $114.08, which we round to $114. That is 8.0% upside. Adding the 4.85% dividend yield, the expected 12-month total return is about 13%. Our base case is close to the Finviz consensus target of $113.64. Recent broker targets range from $97 (TD Cowen, Hold, October 13) through $110 (BNP Paribas Exane, Neutral, raised from $101 on October 16) to $120 (Bank of America, Buy).

Step 4: Cross-check with a dividend discount model. Kimberly-Clark is a “Dividend King” with a 54-year record of raising its dividend, so a dividend discount model is a useful second lens. With a current annual dividend of $5.12 (4 × $1.28):
– 3% long-term dividend growth and a 7.5% required return: $5.12 × 1.03 ÷ (0.075 − 0.03) = $117
– 3% growth and an 8.0% required return: $5.27 ÷ 0.05 = $105
– 3% growth and a 7.0% required return: $5.27 ÷ 0.04 = $132

In other words, today’s price implies investors require about an 8% return from a 3%-growth dividend stream. That is a demanding hurdle for a business with this kind of brand stability. The DDM range is consistent with our $114 base case.

Step 5: Pro forma Kimberly-Clark Kenvue earnings (our estimates). To frame the bull case, we combine the two companies on a simple basis:
– Kimberly-Clark consensus forward EPS of $7.36 × 332.56 million shares ≈ $2.45 billion of net income.
– Kenvue consensus forward EPS of $1.25 × about 1.92 billion shares (Kenvue market cap of $36.32 billion ÷ $18.91 share price) ≈ $2.40 billion.
– We subtract about $0.2 billion of after-tax interest on new acquisition debt (est.).
– The combined company would have about 612.6 million shares (332.6 million existing plus about 280 million new).

That gives pre-synergy pro forma EPS of about $7.58 (est.), roughly in line with Kimberly-Clark’s standalone figure. Management guided at announcement that the deal would be accretive to adjusted EPS by year two, so year one may show some dilution from integration costs and reinvestment.

The upside comes from synergies. Using management’s $2.1 billion net run-rate figure and a 24% tax rate (our assumption) gives about $1.6 billion after tax, or about $2.61 per pro forma share at full run-rate (est.), expected about three years after closing. These figures exclude purchase-accounting amortization, consistent with how both companies report adjusted EPS.

Scenario	Assumption	EPS Basis	Multiple	Price Target	vs. $105.57
Bull	Deal closes on time; ~55% of synergies realized by 2028; China recovers	$9.00 (2028E, est.)	14.5x	$130	+23%
Base	Steady execution; modest re-rating on deal close	$7.36 (consensus forward)	15.5x	$114	+8%
Bear	Synergy slippage; adverse Tylenol litigation; dividend coverage concerns	$6.80 (est.)	12.5x	$85	-19.5%

A 25/50/25 probability weighting gives an expected value of about $111. Adding the dividend, the risk/reward is positive but not dramatic: roughly 10–13% expected total return with a downside of about 20% if things go wrong.

Do we agree with consensus? Mostly. Our $114 base target is in line with the ~$114 consensus, and we share the Street’s caution about near-term organic growth. Where we differ is in the weight we give the deal. Most Hold-rated analysts appear to treat the Kenvue synergies as a distant, uncertain benefit. We think the narrowing merger-arbitrage spread, the EU approval and management’s specific $1.9 billion cost target justify giving partial credit now. The bull case is where that credit pays off.

6. Risk Factors

Risk 1: Tylenol acetaminophen litigation inherited through the Kimberly-Clark Kenvue deal. This is the most important risk to the thesis. In July 2026, a U.S. federal appeals court revived more than 500 lawsuits alleging that prenatal acetaminophen use causes autism or ADHD. The court reinstated three plaintiff experts who had previously been excluded. It did not rule that Tylenol causes autism, and Kenvue maintains that the science shows no proven link. Several large studies and systematic reviews support that position. Separately, Texas Attorney General Ken Paxton has sued Kenvue, alleging it downplayed the risk. Reports on the merger agreement say Kimberly-Clark largely cannot use acetaminophen-autism claims to argue a “material adverse effect,” so the litigation risk transfers to Kimberly-Clark shareholders when the deal closes. A large adverse verdict or a mass settlement could cost billions, damage the Tylenol brand and limit the combined company’s ability to pay down debt. We include this scenario in our bear case.

Risk 2: Integration execution and leverage. Combining two companies with about $32 billion of revenue, different cultures and overlapping supply chains is difficult. The synergy plan requires about $2.5 billion of cash costs to achieve. Kimberly-Clark is also running its own Transformation Initiative through 2028 at a cost of about $1.5 billion. Management attention will be stretched. Leverage will also rise. Kimberly-Clark already has about $6.5 billion of long-term debt. It will take on Kenvue’s debt, which we estimate at about $8.7 billion based on Finviz’s 0.82 Debt/Equity ratio and Kenvue’s book equity, and it will need new borrowing to fund the $6.7 billion cash portion of the consideration. In Q2 2026, the company entered into $4.3 billion of forward-starting interest-rate swaps ahead of that issuance. If synergies arrive late, or borrowing costs rise further, the earnings bridge to our bull case breaks.

Risk 3: Dividend coverage and category weakness. Dividends absorbed 101% of 2025 free cash flow and 96% of first-half 2026 free cash flow. At $5.12 per share, the dividend is about 70% of consensus forward EPS. Kimberly-Clark’s 54-year record of dividend increases is a core reason many investors own the stock. Any sign that the dividend may stop growing would hurt the share price more than an earnings miss would. At the same time, category growth is only about 1.7%, North American consumers are trading down, and the China recovery is not yet proven. If organic growth stays negative (Q3 2026 preliminary organic sales were -1.3%) while cash costs from the deal and transformation peak, the board may need to choose between debt reduction and dividend growth.

There are also smaller risks. Pulp and resin costs could spike. Foreign exchange swings affect IPC results. A U.S. recession would accelerate trading down to private label. The European feminine-care divestiture required by the EU must be completed on acceptable terms.

7. Conclusion and Exit Plan

Investment rating: Buy (income-oriented), base-case target $114.

Kimberly-Clark is not a fast-growth story. It is a mature, brand-led staples company in the middle of a major transformation. The Kimberly-Clark Kenvue deal is now close to completion: shareholder approval, the HSR clearance and the EU approval are all done, and the arbitrage spread is about three cents. The preliminary Q3 beat ($1.70 adjusted EPS against ~$1.59 expected), combined with the company’s third-party retest results showing no formamide, suggests the worst of 2026’s operational problems may have passed, though China’s regulatory probe has not concluded.

At 14.35x forward earnings, about 39% below the high-quality staples peer group, with a 4.85% dividend yield, investors are being paid to wait for synergies. Our base case expects about 13% total return over 12 months (8% price upside plus the dividend). The bull case offers 23% upside plus the yield, if synergy delivery starts strongly. The bear case, about 20% downside, is driven mainly by Tylenol litigation and integration risk. That asymmetry is acceptable for income-focused investors who size the position appropriately.

Entry price range: $98–$106. At $98, the forward P/E falls to about 13.3x and the yield rises to about 5.2%, which compensates for litigation uncertainty. Above $110, the remaining upside to our base case becomes too thin, and we would wait for a pullback or for evidence that the bull case is materializing.

Exit conditions:
– Target achieved: trim one-third of the position at $114 (base case). Consider selling another third at $125–$130 if synergy guidance after closing points to the bull case.
– Fundamental break — sell if any of the following occur:
1. Management cuts or freezes the dividend.
2. The $1.9 billion cost-synergy target is reduced or delayed by more than a year.
3. A court issues a large adverse verdict in the acetaminophen litigation, or the company announces a mass settlement that would push net leverage materially higher.
4. Organic sales growth stays negative for three or more consecutive quarters after China laps the 2026 disruption.
– Time-based: reassess after the Q4 2026 results in early 2027, which should include the first combined guidance if the deal closes as expected, or within six months, whichever comes first.

What to watch next:
– Final Q3 results on November 5, 2026
– The Kenvue deal closing date and the financing terms of the new acquisition debt
– The first combined 2027 guidance and synergy phasing
– China diaper sales trends
– Rulings in the acetaminophen litigation

Item	Detail
Company	Kimberly-Clark Corporation (KMB)
Current Price	$105.57
Target Price	$114 (Base) / $130 (Bull) / $85 (Bear)
Upside	8.0% (plus 4.85% dividend yield)
Rating	Buy
Key Thesis	The Kenvue deal is near closing; 14.4x forward P/E and a 4.85% yield underprice $2.1B of net synergies
Main Risk	Tylenol acetaminophen litigation inherited from Kenvue; integration and leverage execution

—

Disclaimer

This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-10-17) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.